Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia

Molecular Psychiatry

Volumn 20, Issue 9, 2015, Pages 1091-1100

  Banerjee, A ^a   Wang, H Y ^b   Borgmann Winter, K E ^a   MacDonald, M L ^a   Kaprielian, H ^a   Stucky, A ^b   Kvasic, J ^b   Egbujo, C ^a   Ray, R ^a   Talbot, K ^a   Hemby, S E ^c   Siegel, S J ^a   Arnold, S E ^a   Sleiman, P ^d   Chang, X ^d   Hakonarson, H ^d   Gur, R E ^a   Hahn, C G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSBINDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN KINASE C; PROTEIN KINASE P60; PROTEIN TYROSINE PHOSPHATASE; PYK 2 PROTEIN; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE ALPHA; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; HYPOACTIVITY; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CASE CONTROL STUDY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; KNOCKOUT MOUSE; METABOLISM; MOUSE; NERVE CELL PLASTICITY; PATHOLOGY; PHOSPHORYLATION; PREFRONTAL CORTEX;

ANIMALS; BRAIN; CASE-CONTROL STUDIES; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICE; MICE, KNOCKOUT; NEURONAL PLASTICITY; PHOSPHORYLATION; POST-SYNAPTIC DENSITY; PREFRONTAL CORTEX; PROTEIN INTERACTION MAPS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84940440406     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.115     Document Type: Article

References (65)

1. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26: 365-384.
2. Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011; 3: 102mr102.
3. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012; 37: 4-15.
4. Farber NB. The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 2003; 1003: 119-130.
5. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
6. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
7. Moghaddam B, Krystal JH. Capturing the angel in 'angel dust': twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 2012; 38: 942-949.
8. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-436.
9. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR et al. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatry 2012; 2: e137.
10. Noetzel MJ, Jones CK, Conn PJ. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. Discov Med 2012; 14: 335-343.
11. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007; 92: 203-209.
12. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-530.
13. Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014; 19: 20-29.
14. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996; 16: 19-30.
15. Kristiansen LV, Patel SA, Haroutunian V, Meador-Woodruff JH. Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. Synapse 2010; 64: 495-502.
16. Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM, Moore LT et al. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry 2013; 18: 1185-1192.
17. McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994; 74: 723-760.
18. Salter MW. Cellular neuroplasticity mechanisms mediating pain persistence. J Orofac Pain 2004; 18: 318-324.
19. Coultrap SJ, Bayer KU. CaMKII regulation in information processing and storage. Trends Neurosci 2012; 35: 607-618.
20. Hsin H, Kim MJ, Wang CF, Sheng M. Proline-rich tyrosine kinase 2 regulates hippocampal long-term depression. J Neurosci 2010; 30: 11983-11993.
21. MacDonald JF, Kotecha SA, Lu WY, Jackson MF. Convergence of PKC-dependent kinase signal cascades on NMDA receptors. Curr Drug Targets 2001; 2: 299-312.
22. Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 2004; 5: 317-328.
23. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci 2000; 3: 661-669.
24. Kennedy MB. The postsynaptic density at glutamatergic synapses. Trends Neurosci 1997; 20: 264-268.
25. Tang TT, Yang F, Chen BS, Lu Y, Ji Y, Roche KW et al. Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression. Proc Natl Acad Sci USA 2009; 106: 21395-21400.
26. Ma TM, Abazyan S, Abazyan B, Nomura J, Yang C, Seshadri S et al. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Mol Psychiatry 2013; 18: 557-567.
27. Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 2007; 16: 129-141.
28. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH et al. Altered neur-egulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006; 12: 824-828.
29. Agim ZS, Esendal M, Briollais L, Uyan O, Meschian M, Martinez LA et al. Discovery, validation and characterization of Erbb4 and Nrg1 haplotypes using data from three genome-wide association studies of schizophrenia. PLoS One 2013; 8: e53042.
30. Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 2000; 275: 41439-41446.
31. Takahashi N, Nielsen KS, Aleksic B, Petersen S, Ikeda M, Kushima I et al. Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase alpha to schizophrenia. Biol Psychiatry 2011; 70: 626-635.
32. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014; 506: 179-184.
33. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 2012; 17: 142-153.
34. Kalia LV, Pitcher GM, Pelkey KA, Salter MW. PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex. EMBO J 2006; 25: 4971-4982.
35. Pitcher GM, Kalia LV, Ng D, Goodfellow NM, Yee KT, Lambe EK et al. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med 2011; 17: 470-478.
36. Hahn CG, Banerjee A, Macdonald ML, Cho DS, Kamins J, Nie Z et al. The post-synaptic density of human postmortem brain tissues: an experimental study paradigm for neuropsychiatric illnesses. PLoS One 2009; 4: e5251.
37. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience 2012; 251: 90-107.
38. Lewis DA. Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia. Dialogues Clin Neurosci 2009; 11: 269-280.
39. Goghari VM, Sponheim SR, MacDonald AW 3rd. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev 2010; 34: 468-486.
40. Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology 2011; 36: 316-338.
41. Cox MM, Tucker AM, Tang J, Talbot K, Richer DC, Yeh L et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav 2009; 8: 390-397.
42. Steele JE, Bowen DM, Francis PT, Green AR, Cross AJ. Spermidine enhancement of [3H]MK-801 binding to the NMDA receptor complex in human cortical membranes. Eur J Pharmacol 1990; 189: 195-200.
43. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J Neurosci 2009; 29: 10961-10973.
44. Sleiman P, Wang D, Glessner J, Hadley D, Gur RE, Cohen N et al. GWAS meta analysis identifies TSNARE1 as a novel Schizophrenia/Bipolar susceptibility locus. Sci Rep 2013; 3: 3075.
45. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013; 18: 497-511.
46. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011; 43: 977-983.
47. Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP et al. Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010; 49: 884-897.
48. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.
49. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM et al. A versatile gene-based test for genome-wide association studies. Am J Hum Genet 2010; 87: 139-145.
50. Razick S, Magklaras G, Donaldson IM. iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinformatics 2008; 9: 405.
51. MacDonald ML, Ciccimaro E, Prakash A, Banerjee A, Seeholzer SH, Blair IA et al. Biochemical fractionation and stable isotope dilution liquid chromatography-mass spectrometry for targeted and microdomain-specific protein quantification in human postmortem brain tissue. Mol Cell Proteomics 2012; 11: 1670-1681.
52. Ebert B, Andersen S, Hjeds H, Dickenson AH. Dextropropoxyphene acts as a noncompetitive N-methyl-D-aspartate antagonist. J Pain Symptom Manage 1998; 15: 269-274.
53. Kornhuber J, Mack-Burkhardt F, Kornhuber ME, Riederer P. [3H]MK-801 binding sites in post-mortem human frontal cortex. Eur J Pharmacol 1989; 162: 483-490.
54. Codazzi F, Di Cesare A, Chiulli N, Albanese A, Meyer T, Zacchetti D et al. Synergistic control of protein kinase Cgamma activity by ionotropic and metabotropic glu-tamate receptor inputs in hippocampal neurons. J Neurosci 2006; 26: 3404-3411.
55. Takagi N, Besshoh S, Morita H, Terao M, Takeo S, Tanonaka K. Metabotropic glutamate mGlu5 receptor-mediated serine phosphorylation of NMDA receptor subunit NR1 in hippocampal CA1 region after transient global ischemia in rats. Eur J Pharmacol 2010; 644: 96-100.
56. Gurd JW, Bissoon N. The N-methyl-D-aspartate receptor subunits NR2A and NR2B bind to the SH2 domains of phospholipase C-gamma. J Neurochem 1997; 69: 623-630.
57. Dwivedi Y, Pandey GN. Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide-specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain. J Pharmacol Exp Ther 1999; 291: 688-704.
58. Marballi K, Cruz D, Thompson P, Walss-Bass C. Differential neuregulin 1 cleavage in the prefrontal cortex and hippocampus in schizophrenia and bipolar disorder: preliminary findings. PLoS One 2012; 7: e36431.
59. Tang J, LeGros RP, Louneva N, Yeh L, Cohen JW, Hahn CG et al. Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum Mol Genet 2009; 18: 3851-3863.
60. Talbot K, Louneva N, Cohen JW, Kazi H, Blake DJ, Arnold SE. Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location. PLoS One 2011; 6: e16886.
61. Ohnishi H, Murata Y, Okazawa H, Matozaki T. Src family kinases: modulators of neurotransmitter receptor function and behavior. Trends Neurosci 2011; 34: 629-637.
62. Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008; 33: 18-41.
63. Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol 2012; 22: 496-508.
64. Li HB, Jackson MF, Yang K, Trepanier C, Salter MW, Orser BA et al. Plasticity of synaptic GluN receptors is required for the Src-dependent induction of long-term potentiation at CA3-CA1 synapses. Hippocampus 2011; 21: 1053-1061.
65. Perez-Otano I, Ehlers MD. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci 2005; 28: 229-238.